Posts Tagged ‘TYPE’

Blueprint of Stem Cell Wiring Gives Scientists Control

In SCIENCE & STEM CELLS on March 3, 2012 at 12:47 am


Blueprint of Stem Cell Wiring Gives Scientists Control

March 2, 2012

Despite the promise associated with the therapeutic use of human stem cells, a complete understanding of the mechanisms that control the fundamental question of whether a stem cell becomes a specific cell type within the body or remains a stem cell has-until now-eluded scientists.

A Univ. of Georgia study published in today’s edition of the journal Cell Stem Cell, however, creates the first ever blueprint of how stem cells are wired to respond to the external signaling molecules to which they are constantly exposed. The finding, which reconciles years of conflicting results from labs across the world, gives scientists the ability to precisely control the development, or differentiation, of stem cells into specific cell types.

Laboratory Equipment – Blueprint of Stem Cell Wiring Gives Scientists Control.

ADULT Stem Cell Therapy Reverses Diabetes – CBS 42

In VICTORIES & SUCCESS STORIES on January 18, 2012 at 9:12 am

ADULT Stem Cell Therapy Reverses Diabetes

BIRMINGHAM, Ala. (Ivanhoe Newswire)- Type 1 diabetes is caused by the body’s own immune system attacking its pancreatic islet beta cells and requires daily injections of insulin to regulate the patient’s blood glucose levels.

A new method found in the BioMed Central’s open access journal BMC Medicine uses stem cells from cord blood to reeducate the T cells in a diabetic’s blood to restart the pancreatic function and reduce the need for insulin. In Stem Cell Educator therapy, lymphocytes were separated from a patient’s blood over immobilized donated cord blood stem cells. After two or three hours in the device the revamped lymphocytes are returned to the patient. Progress was checked at 4, 12, 24 and 40 weeks after therapy.

After 12 weeks results showed an increase in C-peptide levels. C-peptide is a protein fragment created from insulin that can be used to determine how well beta cells are working. Levels increased at 24 weeks and remained the same at the end of the study, meaning that the patient’s daily dose of insulin could be reduced. Also results showed that the glycated hemoglobin (HbA1C) indicator of long term glucose control also dropped for people receiving the treatment.

Dr Yong Zhao, from University of Illinois at Chicago, was quoted as saying, “We also saw an improved autoimmune control in these patients. Stem Cell Educator therapy increased the percentage of regulatory T lymphocytes in the blood of people in the treatment group. Other markers of immune function, such as TGF-beta1 also improved. Our results suggest that it is this improvement in autoimmune control, mediated by the autoimmune regulator AIRE in the CBSC, which allows the pancreatic islet beta cells to recover.”

Source: BMC Medicine, January 2012

Stem Cell Therapy Reverses Diabetes – CBS 42 Birmingham, AL News Weather Sports.

Reuters Health Update

In ALL ARTICLES on April 22, 2011 at 3:38 pm

New studies point to clot risk of Bayer’s Yasmin
April 21, 2011 06:34 PM ET
FRANKFURT (Reuters) – New evidence emerged on Friday that women taking Bayer’s best-selling contraceptive Yasmin may run a higher risk of dangerous blood clots than those using older birth-control pills. | Full Article
No evidence coffee ups risk of high blood pressure
April 22, 2011 07:52 AM ET
NEW YORK (Reuters Health) – Despite earlier concerns, downing lots of coffee doesn’t seem to increase the risk of high blood pressure, according to a new report — but the evidence isn’t conclusive. | Full Article
Many kids with diabetes have other immune diseases
April 21, 2011 05:29 PM ET
NEW YORK (Reuters Health) – A third of children with type 1 diabetes have signs of other immune system disorders when they get diagnosed with diabetes, according to a new study. | Full Article

About Stem Cell Treatment for Diabetes (from eHow.com)

In VICTORIES & SUCCESS STORIES on April 4, 2011 at 2:38 pm
About Stem Cell Treatment for Diabetes

Traditionally diabetics administer insulin injections in an attempt to replace the function of the pancreas. Studies show there is a new alternative for diabetes treatment by use of stem cells. The use of stem cells can stop the progression of diabetes, and in some cases, eliminate the need for insulin injections.


  1. What is Type 1 Diabetes?
    • Type 1 diabetes, or juvenile diabetes, occurs when the body’s immune system mistakenly attacks the insulin producing cells in the pancreas. Without insulin, the body’s cells cannot absorb glucose. This leaves the glucose in the bloodstream. High blood glucose levels can cause organ deterioration, ketoacidosis, coma and even death.

    What are Stem Cells?
    • Stem cells can convert themselves to special cells like insulin producing beta cells in the pancreas. They also have the ability to repair organs and tissues of the body by dividing themselves without limit. They can be extracted from bone marrow, muscle and the brain. These are called adult stem cells. The cells taken from these areas are able to generate replacements. This is a phenomenal step toward treating diseases like diabetes.

    • The objective of diabetic stem cell treatment is to stop the immune system from attacking the beta cells of the pancreas. It is not possible to reverse diabetes with this method or any other method. The stem cell treatment can only stop the degeneration of the pancreas. Because of this, long-term diabetics will not benefit from this treatment. The best candidates for diabetic stem cell treatment are newly diagnosed patients. These diabetics still have a pancreas that can be saved.

    Diabetes Stem Cell Treatment Study
    • Fifteen diabetic patients with ages ranging from 14 to 31 were part of a stem cell treatment study in Brazil. These patients were given drugs and hormones to move their stem cells from the bone marrow to the bloodstream. Doctors used a device to remove the cells from the bloodstream. After two weeks, the patients received chemotherapy to destroy their current immune system over the course of five days. The patients rested for a day, and then were administered their own stem cells for 12 days. This created a new immune system that would not attack their pancreas.

    • To review more studies like this: https://repairstemcell.wordpress.com/diabetes-stem-cells/
    Results of Brazil study
    • The results of this treatment enabled 12 patients to stop taking insulin right away. Over the course of 18 months, two patients have not needed insulin injections. Five patients have been insulin-free for 23 months. One patient received no effect from the treatment. Doctors determined the patient’s diabetes progressed too far. According to Dr. Jay Skyler, with the Diabetes Research Institute at the University of Miami Miller School of Medicine, even if insulin shots are still needed, the treatment is a success if it saves beta cells from being destroyed.


Adult Stem Cells – Diabetes type1

In VICTORIES & SUCCESS STORIES on June 22, 2010 at 2:44 pm

Great article and great site written by the mother of a boy who had a transplant from his own stem cells (autologous) for Type1 Diabetes and Asperger’s Syndrome! -dg

Diabetes type 1 and the Cure – What I feel Are the Most Promising

I first wanted to hear if from a child’s perspective. Here it goes:

Mom: What do you feel is the cure for diabetes?

Gabriel: What I had done.

Mom: What did you have done?

Gabriel: Stem Cells from my body.

Mom: How do you feel?

Gabriel: Good. I thank God. I just hope that my anteebuddies don’t attack my new cells.

Mom: How about if one day your Endo gives you a sheet of paper and allowed to choose one to cure you. Let’s assume you were given these options. Which one would you choose?

1. Adult stem cell transplant (what you had done)

2. Artificial pancreas

3. Islet Cell Transplantation from a donor pancreas

4. Islet Sheet

5. Pig Islet Cell Transplant

6. Stem Cell Therapy Drug(from donor) via injections

I explained the above in child’s terminology.

Gabriel: I like #1. What I had done. I know what to expect and it didn’t hurt and it was safe. I am doing well.

Mom: Why not the others?

Gabriel: I don’t know about pigs in my body. I may become one. I don’t get it. I don’t want # 2 because I already wear an insulin pump and I don’t want more things on my body. I am full of holes and this is really not the cure. It’s just something better than the pump. I don’t know about the others.

Mom: How about #6.

Gabriel: It’s something like #1, but it’s from other people’s body not my own. I want my own body to go back into my body. Why can’t they do #6 with the person’s own body? Oh, on #4…..I don’t know if that sheet will melt or pop inside my body. Do I need to go back and get a new one? how do they get the sheet inside my body? Mommy, remember when we travel and we go through those bars at the airport and I take off my pump? Would the sheet inside my body make the security bar ring? and then I cannot take it off. How about when I go to the doctor and get X-rays will it explode the sheet? I don’t think I like #4.

Mom: Good questions and I don’t know the answer. I’m assuming it will be fine.

Mom: So, what are you going to do when you are cured?

Gabriel: I will close my eyes and look at the sky and raise my hands up really really high and thank God for no more insulin, no more counting carbs, no more backpack wherever I go! And then, and then, ummmm… I will have a bubble gum party. Yes! I will have a bubble gum party!

Mom: Who are you going to invite to the bubble gum party?

Gabriel: Everyone that wants to come.

Mom: Who will pay this big party?

Gabriel: hmmmmm..You and Dad. Maybe JDRF.

via Adult Stem Cells – Diabetes type1.

DIABETES & STEM CELLS – A brief history

In VICTORIES & SUCCESS STORIES on October 2, 2009 at 1:03 pm


In VICTORIES & SUCCESS STORIES on September 14, 2009 at 12:37 am

C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus

Carlos E. B. Couri, MD, PhD; Maria C. B. Oliveira, MD; Ana B. P. L. Stracieri, MD, PhD; Daniela A. Moraes, MD; Fabiano Pieroni, MD, PhD; George M. N. Barros, MD; Maria Isabel A. Madeira, MD; Kelen C. R. Malmegrim, PhD; Maria C. Foss-Freitas, MD, PhD; Belinda P. Simões, MD, PhD; Edson Z. Martinez, PhD; Milton C. Foss, MD, PhD; Richard K. Burt, MD; Júlio C. Voltarelli, MD, PhD

JAMA. 2009;301(15):1573-1579.

Context In 2007, the effects of the autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT) in 15 patients with type 1 diabetes mellitus (DM) were reported. Most patients became insulin free with normal levels of glycated hemoglobin A1c (HbA1c) during a mean 18.8-month follow-up. To investigate if this effect was due to preservation of beta-cell mass, continued monitoring was performed of C-peptide levels after stem cell transplantation in the 15 original and 8 additional patients.

Objective To determine C-peptide levels after autologous nonmyeloablative HSCT in patients with newly diagnosed type 1 DM during a longer follow-up.

Design, Setting, and Participants A prospective phase 1/2 study of 23 patients with type 1 DM (aged 13-31 years) diagnosed in the previous 6 weeks by clinical findings with hyperglycemia and confirmed by measurement of serum levels of anti–glutamic acid decarboxylase antibodies. Enrollment was November 2003-April 2008, with follow-up until December 2008 at the Bone Marrow Transplantation Unit of the School of Medicine of Ribeirão Preto, Ribeirão Preto, Brazil. Hematopoietic stem cells were mobilized via the 2007 protocol.

Main Outcome Measures C-peptide levels measured during the mixed-meal tolerance test, before, and at different times following HSCT. Secondary end points included morbidity and mortality from transplantation, temporal changes in exogenous insulin requirements, and serum levels of HbA1c.

Results During a 7- to 58-month follow-up (mean, 29.8 months; median, 30 months), 20 patients without previous ketoacidosis and not receiving corticosteroids during the preparative regimen became insulin free. Twelve patients maintained this status for a mean 31 months (range, 14-52 months) and 8 patients relapsed and resumed insulin use at low dose (0.1-0.3 IU/kg). In the continuous insulin–independent group, HbA1c levels were less than 7.0% and mean (SE) area under the curve (AUC) of C-peptide levels increased significantly from 225.0 (75.2) ng/mL per 2 hours pretransplantation to 785.4 (90.3) ng/mL per 2 hours at 24 months posttransplantation (P < .001) and to 728.1 (144.4) ng/mL per 2 hours at 36 months (P = .001). In the transient insulin–independent group, mean (SE) AUC of C-peptide levels also increased from 148.9 (75.2) ng/mL per 2 hours pretransplantation to 546.8 (96.9) ng/mL per 2 hours at 36 months (P = .001), which was sustained at 48 months. In this group, 2 patients regained insulin independence after treatment with sitagliptin, which was associated with increase in C-peptide levels. Two patients developed bilateral nosocomial pneumonia, 3 patients developed late endocrine dysfunction, and 9 patients developed oligospermia. There was no mortality.

Conclusion After a mean follow-up of 29.8 months following autologous nonmyeloablative HSCT in patients with newly diagnosed type 1 DM, C-peptide levels increased significantly and the majority of patients achieved insulin independence with good glycemic control.

Trial Registration clinicaltrials.gov Identifier: NCT00315133
Author Affiliations: Departments of Clinical Medicine (Drs Couri, Oliveira, Stracieri, Moraes, Pieroni, Barros, Madeira, Malmegrim, Foss-Freitas, Simões, Foss, and Voltarelli) and Social Medicine (Dr Martinez), School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil; and Division of Immunotherapy, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Dr Burt).




Stem Cell Research Uncovers Mechanism for Type 2 Diabetes

Published on 12 February 2009, 14:33 Last Update: 17 minute(s) ago by Insciences

Tags: Stem Cell Diabetes Medicine Progenitor cells

LA JOLLA, Calif., February 12, 2009—Taking clues from their stem cell research, investigators at the University of California San Diego (UC San Diego) and Burnham Institute for Medical Research (Burnham) have discovered that a signaling pathway involved in normal pancreatic development is also associated with type 2 diabetes. Their findings, published online January 9 in Experimental Diabetes Research, could provide a potential new target for therapy.

Pamela Itkin-Ansari, Ph.D., assistant adjunct professor at the UC San Diego School of Medicine and Burnham; Fred Levine, M.D., Ph.D., professor and director of the Sanford Children’s Health Research Center at Burnham, and colleagues showed that the Wnt signaling pathway is up-regulated in insulin producing cells of pancreases from adults with type 2 diabetes…

via insciences.org – Stem Cell Research Uncovers Mechanism for Type 2 Diabetes.

%d bloggers like this: